VALENCIA, Spain, May 29, 2025 — ARTHEx Biotech S.L., a biotechnology firm in the clinical stage dedicated to creating cutting-edge treatments by altering gene expression, today announced its attendance at the Jefferies Global Healthcare Conference in 2025, scheduled for June 3-5, 2025.
Frédéric Legros, the Executive Chairman and CEO, is scheduled to engage in individual meetings with investors throughout the conference.
About ARTHEx Biotech
ARTHEx Biotech is a biotechnology firm in the clinical phase focused on the development of innovative therapies via gene expression modulation. The company’s primary investigational drug, ATX-01, is currently undergoing assessment in the Phase I-IIa ArthemiR
trial for the treatment of myotonic dystrophy type 1 (DM1), a rare neuromuscular condition. Furthermore, ARTHEx is furthering its internal discovery platform to pinpoint and create microRNA modulators for additional ailments characterized by significant unmet medical requirements, encompassing genetically determined diseases such as DM1. The company’s headquarters are situated in Valencia, Spain.
For additional details, please visit and connect with us on LinkedIn.
|
Company Contact. |
Investor and Media Contact |
|
Frédéric Legros |
Amy Conrad |
SOURCE ARTHEx Biotech
“`